![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 38, 26907-26911, September 17, 1999
From the The heme of neuronal nitric-oxide synthase
participates in oxygen activation but also binds self-generated NO
during catalysis resulting in reversible feedback inhibition. We
utilized point mutagenesis to investigate if a conserved tryptophan
residue (Trp-409), which engages in The free radical nitric oxide
(NO)1 has diverse roles in
cellular processes including blood flow, neurotransmission, and the immune response (1-3). NO is synthesized by a family of enzymes termed
NO synthases (NOSs). All NOSs catalyze a two-step, NADPH-and O2-dependent oxidation of
L-arginine (Arg) to NO and citrulline forming
N The NOS heme iron has a proximal cysteine thiolate ligand (12-14), as
occurs in the cytochrome P450s. This enables a similar chemistry for
oxygen activation and mixed function oxidation of substrate (4, 5).
However, the heme environments in NOS and the cytochrome P450s differ
in a number of important ways. Crystal structures show that
H4B binds at the heme edge in NOS perpendicular to its
plane (12-14). Two conserved aromatic residues (Phe-584 and Trp-409 in
rat nNOS) engage in aromatic stacking with the heme on its distal and
proximal sides, respectively (Fig. 1).
This aromatic stacking is absent in cytochrome P450s but is present in
peroxidases and influences their electronic and catalytic properties
(15). NOS crystal structures predict that the indole nitrogen of
Trp-409 hydrogen bonds with the cysteine thiolate heme ligand in nNOS.
In cytochrome P450s, hydrogen bonding to the coordinating thiolate is
minimal, but it does occur in the thiolate-ligated hemeprotein
chloroperoxidase (16). Aromatic and hydrogen bond interactions of
Trp-409 in nNOS could conceivably influence heme iron electronegativity
(17, 18), but its actual role has not been tested.
The nNOS heme also binds self-generated NO during NO synthesis (19).
The resulting ferrous heme-NO complex is inactive but resumes normal
catalysis upon O2-dependent decay of the NO
complex. This distinguishes nNOS from cytochrome P450s, which usually
are irreversibly inactivated if NO binds to their ferrous heme (20). Because decay of the ferrous-NO complex is relatively slow, a majority
of nNOS enzyme molecules (70-90%) exist as an NO complex during
steady-state NO synthesis (19). Although this suggests that heme-NO
binding is an important regulator of NOS catalysis, it is currently
unclear what, if any, structural features that are unique to NOS allow
it to function in this capacity.
To address this issue, we used site-directed mutagenesis to investigate
what role Trp-409 has in regulating nNOS activity. Surprisingly,
substitution with Phe or Tyr generated mutants that had greater NO
synthesis than wild-type nNOS. Mutant hyperactivity appeared to result
from combined changes in electron flux and heme-NO complex formation
during the steady state. Our results emphasize the importance of NO
complex formation in regulating nNOS activity and reveal that Trp-409
plays a key role in the process.
Materials--
All reagents and materials were obtained from
Sigma or sources previously reported (18, 19).
Molecular Biology--
Wild-type nNOS and mutants containing a
His6 tag attached to their N terminus were overexpressed in
Escherichia coli strain BL21 (DE3) using a modified pCWori
vector and were purified as described (21, 27). Restriction digestions,
cloning, and bacterial growth were performed using standard procedures
(22). Transformations were done using a TransformAid kit from MBI
Fermentas. DNA fragments were isolated using the AgarACE enzyme
protocol from Promega. Site-directed mutagenesis was done using the
Quick Change polymerase chain reaction in vitro mutagenesis
kit from Stratagene. Incorporated mutations were confirmed by DNA
sequencing at the Cleveland Clinic core facility. DNAs containing the
desired mutations were transformed into E. coli
for protein expression.
Oligonucleotides used to construct site-directed mutants in nNOS were
synthesized by Life Technologies, Inc. or by Integrated DNA
Technologies. Silent mutations coding for restriction sites were
incorporated into the oligonucleotides to aid in screening. Mutations
(bold), silent restriction sites (underlined),
and their corresponding oligonucleotides were as follows:
W409F-NheI-sense: GCATGCCTTCCGGAACGCTAGCCGATGTGTGGGCAG;
W409F-antisense: CTGCCCACACATCGGCTAGCGTTCCGGAAGGCATGC;
W409Y-NheI-sense:
GCATGCCTACCGGAACGCTAGCCGATGTGTGGGCAG; and
W409Y-antisense: CTGCCCACACATCGGCTAGCGTTCCGGTAGGCATGC.
Expression and Purification of Wild-type and nNOS
Mutants--
Wild-type and mutant nNOS were expressed in E. coli and purified as described previously (21, 27). UV-visible
spectra was recorded on a Hitachi U3110 Spectrophotometer in the
absence or presence of 20 µM H4B and 1 mM Arg. The ferrous-CO adduct absorbing at 444 nm was used
to quantitate the heme protein content using an extinction coefficient
of 74 mM NO Synthesis, NADPH Oxidation, and Cytochrome c
Reduction--
The initial rate of NO synthesis, NADPH oxidation, or
cytochrome c reduction by wild type and mutants was
quantitated at 25 °C as described earlier (9).
Ferrous-Nitrosyl Complex Formation during Steady State--
0.6
µM nNOS was diluted in an air-saturated 40 mM
EPPS buffer, pH 7.6, containing 0.9 mM EDTA, 3 µM CaM, 200 µM DTT, 20 µM H4B, 80 µM NADPH, and 1 mM Arg;
final volume 1 ml. Reactions were started by adding 1.2 mM
Ca2+ and monitored by wavelength scanning at 15 °C.
Ferric- and Ferrous-NO Complex Formation under Anaerobic
Conditions--
Concentrated small amounts of nNOS or mutants were
placed into an anaerobic cuvette with 4 µM
H4B, 1 mM Arg, and 200 µM DTT and
made anaerobic by repeated cycles of evacuation and equilibration with
deoxygenated argon gas. A 40 mM EPPS buffer containing 4 µM H4B, 1 mM Arg, and 200 µM DTT was separately made anaerobic, and 1 ml of this
solution was transferred to the cuvette. NO gas was added to the head
space and dissolved by mixing. Dithionite solution was then added in
some cases.
H2O2-dependent NOHA
Oxidation--
H2O2-dependent nNOS
oxidation of NOHA to nitrite was assayed in 96-well microplates at
30 °C as described previously (23) with modification. The assay
volume was 100 µl and contained 40 mM EPPS, pH 7.6, 250 nM nNOS or mutants, 1 mM NOHA, 1 mM
DTT, 25 units/ml superoxide dismutase, 0.5 mM EDTA, and 4 µM H4B. Reactions were initiated by adding 30 mM H2O2 and stopped after 10 min by adding 1300 units of catalase. Nitrite was detected at 550 nm using the
Griess reagent (100 µl) and quantitated based on nitrite standards.
Arg Binding--
Arg binding affinity was studied at 30 °C by
perturbation difference spectroscopy according to methods described
previously (24). The buffer contained 40 mM EPPS, 5%
glycerol, 1 mM DTT, 20 µM H4B,
and 1 or 2 µM enzyme. 10 mM imidazole was
added to the cuvette prior to titration with L-Arg (0-200
µM). The Kd of Arg was calculated by
double reciprocal analysis of the absorbance difference
versus substrate concentration.
The optical spectrum of the W409F and W409Y mutants closely
resembled that of wild-type nNOS at pH 7.6 in the absence of
H4B and Arg (data not shown). Addition of 20 µM H4B and 1 mM arginine to
either mutant caused a spectral shift from low spin to high spin,
indicating that these molecules bound. Dithionite reduction in the
presence of Arg, H4B, and CO produced a 444-nm absorbance peak for the ferrous-CO complex in both cases, indicating that their
heme iron ligation is the same as in wild-type nNOS. Arg binding
affinities were determined by spectral perturbation in the presence of
10 mM imidazole and 20 µM H4B
(data not shown). Arg completely displaced bound imidazole during the
titrations, and the Arg Ks values for W409F and
W409Y were 60 and 68 µM, respectively, compared with 55 µM for wild-type nNOS. Thus, Arg and H4B
binding were not significantly perturbed by the mutation of Trp-409 to Tyr or Phe.
Table I compares the catalytic turnover
numbers of wild-type nNOS and the Trp-409 mutants with regard to NO
synthesis from Arg or NOHA, NADPH oxidation, and cytochrome
c reduction in the presence or absence of
Ca2+/CaM. Substitution of Trp-409 with Phe or Tyr altered
rates of NO synthesis and NADPH oxidation but did not alter cytochrome c reduction in any case, suggesting the mutations only
affect the oxygenase domain of nNOS. Surprisingly, the W409F and W409Y mutants had 3- and 1.8-fold faster rates of NO synthesis from Arg
compared with the wild type, respectively. Corresponding rates of NADPH
oxidation were increased, indicating a proportional increase in
electron flux through the enzyme. The calculated NADPH stoichiometries were 1.7, 1.6, and 1.5 mol of NADPH oxidized/mol of NO generated from
Arg for wild-type nNOS, W409F, and W409Y, respectively. These values
are close to the theoretical minimum of 1.5 (4, 6) and therefore
indicate tight coupling between NADPH oxidation and NO synthesis by the
mutants. When NOHA replaced Arg as the substrate, an even greater
hyperactivity was observed for both mutants (Table I).
Tryptophan 409 Controls the Activity of Neuronal Nitric-oxide
Synthase by Regulating Nitric Oxide Feedback Inhibition*
,
,
,
¶
Department of Immunology, Lerner Research
Institute, Cleveland Clinic, Cleveland, Ohio 44195 and the
§ Department of Molecular Biology and the Skaggs Institute
for Chemical Biology, The Scripps Research Institute, La Jolla,
California 92037
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-stacking with the heme and
hydrogen bonds to its axial cysteine ligand, helps control catalysis
and regulation by NO. Surprisingly, mutants W409F and W409Y were
hyperactive compared with the wild type regarding NO synthesis without
affecting cytochrome c reduction, reductase-independent
N-hydroxyarginine oxidation, or Arg and tetrahydrobiopterin
binding. In the absence of Arg, NADPH oxidation measurements showed
that electron flux through the heme was actually slower in the Trp-409
mutants than in wild-type nNOS. However, little or no NO complex
accumulated during NO synthesis by the mutants, as opposed to the wild
type. This difference was potentially related to mutants forming
unstable 6-coordinate ferrous-NO complexes under anaerobic conditions
even in the presence of Arg and tetrahydrobiopterin. Thus, Trp-409 mutations minimize NO feedback inhibition by preventing buildup of an
inactive ferrous-NO complex during the steady state. This overcomes the
negative effect of the mutation on electron flux and results in
hyperactivity. Conservation of Trp-409 among different NOS suggests
that the ability of this residue to regulate heme reduction and NO
complex formation is important for enzyme physiologic function.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-hydroxy-L-arginine (NOHA) as an
intermediate (4, 5). Three different isoforms exist: inducible NOS
(iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS). Both eNOS and
nNOS are constitutively expressed, whereas iNOS is expressed in
response to cytokines or bacterial products. Each NOS is comprised of
an N-terminal oxygenase domain that binds iron protoporphyrin IX
(heme), 6R-tetrahydrobiopterin (H4B), and
L-arginine (Arg) and a C-terminal reductase domain that
binds FMN, FAD, and NADPH (6). To be active, two NOS oxygenase domains
interact to form a homodimer. NOS oxygenase and reductase domains are
linked together on the polypeptide by a calmodulin (CaM) binding
sequence (7, 8). CaM binding activates NO synthesis by triggering
electron transfer from the flavins to the heme (9). Sequential transfer
of electrons enables the heme to bind and activate O2 in
both steps of NO synthesis (10, 11).

View larger version (34K):
[in a new window]
Fig. 1.
Structural model showing positions of Trp-409
and Phe-584 relative to the heme and the heme-binding cysteine in
nNOS. The model is based on published crystal structures for iNOS
and eNOS (12-14). The view is from the proximal side of the heme.
Amino acid residues are numbered, and the heme is a thin stick
representation. A dashed line depicts the hydrogen bond
between an indole nitrogen of Trp-409 and the cysteine thiolate.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 cm
1 (A444-A500).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Comparative analysis of catalytic activities of wild type nNOS and
mutants
To understand how the mutations increased rates of NO synthesis by
nNOS, we first examined mutant activities in the
H2O2-supported NOHA oxidation assay. This
measures nitrite formation and is useful because the reaction does not
require electrons from the reductase domain and does not result in
formation of a heme-NO complex (23). As shown in Fig.
2, initial rates of nitrite formation by
the mutant proteins were equivalent to wild-type nNOS. This suggests that the mutations increase NO synthesis in the NADPH-supported reaction by changing the rate of electron flux and/or the dynamics of
heme-NO complex formation.
|
To examine how the mutations effect electron flux through nNOS, we compared their NADPH oxidation rates under a number of different conditions (Table II). CaM-bound, wild-type nNOS had a relatively high rate of NADPH oxidation in the absence of H4B and Arg, and this rate was increased approximately two times when H4B bound, consistent with previous reports (18). NADPH oxidation rates for the CaM-bound Trp-409 mutants were slower in the absence of Arg and H4B but increased proportionally as for the wild type in response to H4B (~2×). Addition of the heme reduction inhibitor nitro-L-Arg methyl ester (18) to the H4B-bound proteins decreased their NADPH oxidation rates to a level seen for the nNOS reductase domain alone, indicating that any additional NADPH oxidation above this value was associated with heme reduction. Together, these data indicate that electron flux through the heme is actually slower in the two mutants than in wild-type nNOS in the absence of NO synthesis. The addition of Arg to the CaM-bound, H4B-saturated enzymes initiated NO synthesis in all cases and lowered the rate of NADPH oxidation in wild-type nNOS, as reported previously (9, 18). In contrast, the Arg addition increased NADPH oxidation rates in both H4B-bound mutants. To test if NO was involved in modulating the Arg effects, we utilized agmatine, a substrate analog that binds to nNOS without supporting NO synthesis.2 Agmatine decreased NADPH oxidation by wild-type nNOS compared with H4B alone but to a lesser extent than seen with Arg. For the mutants agmatine either did not effect the NADPH oxidation rate (W409F) or only increased it slightly (W409Y). These data show that electron flux through the heme is actually slower in the mutants under all conditions except when NO synthesis is taking place. This suggests that mutant hyperactivity and associated increase in electron flux must arise from a difference in NO interaction with the enzyme.
|
NO down-regulates the rate of NO synthesis and associated electron flux
by binding to the nNOS heme (19). We therefore investigated if NO
binding to the heme was altered by the Trp-409 mutations during aerobic
steady-state catalysis. Fig. 3 shows
wavelength scans of nNOS and mutants before and after activating NO
synthesis at 15 °C. For wild-type nNOS, a significant percentage
accumulated as the 6-coordinate ferrous-NO complex during the
steady-state, as judged by the buildup of characteristic absorbance
peaks at 436 and 560 nm (A and D), as reported
earlier (19, 25). Under the same conditions, the Trp-409 mutants had
either a small (W409F) or no (W409Y) detectable absorbance buildup at
436 nm (B, C, and D), indicating their
6-coordinate NO complexes did not accumulate during steady-state NO
synthesis.
|
Given the above, we investigated if either mutant could form stable
ferric or ferrous NO complexes with authentic NO under an anaerobic
atmosphere in the presence of Arg and H4B, as occurs for
wild-type nNOS (19, 25). Fig. 4,
A-C, shows that wild-type nNOS and both mutants all formed
stable 6-coordinate ferric NO complexes that display a Soret peak at
440 nm and visible peaks at 549 and 580 nm (25). A small amount of
dithionite was then added to reduce each enzyme. This formed a stable
6-coordinate ferrous-NO complex in wild-type nNOS (A) but
generated unstable ferrous-NO complexes in both mutants (B
and C). We conclude that the W409 mutations destabilize the
ferrous-NO complex that normally accumulates during NO synthesis by
nNOS.
|
| |
DISCUSSION |
|---|
|
|
|---|
Mutating conserved residues near the active site of an enzyme
usually diminish activity. This makes the hyperactivity of the Trp-409
nNOS mutants unusual but not unique among hemeproteins. In fact,
mutation of Trp-51 to Phe in yeast cytochrome c peroxidase results in hyperactivity with regard to cytochrome c
oxidation (15). Like Trp-409 in nNOS, Trp-51 engages in
-stacking
with the peroxidase heme (26) but on its distal rather than proximal side as in nNOS. Peroxidase hyperactivity appears to result from a
faster reduction of a compound I-like heme intermediate by the substrate cytochrome c. However, the hyperactivity observed
for our nNOS mutants occurs through a distinct mechanism.
After initiating NO synthesis, nNOS molecules quickly partition between
a catalytically active form and an inactive ferrous-NO complex (19).
This creates two cycles that each have their own rate-limiting step and
together determine the observed rate of NO synthesis during the
steady-state (Fig. 5). A given nNOS
molecule circulates in the active or inactive cycles depending on
whether it binds O2 or NO to the heme. The rate-limiting
step in the active cycle, which leads to NO synthesis, could be
substrate binding, electron transfer, oxygen binding, a bond-making or
-breaking step involved in oxygen activation or product formation, or
product release. It is still unclear which of these is rate-limiting
for wild-type nNOS, but related work clearly shows that heme reduction becomes rate-limiting if it is slowed relative to wild type (27, 28).
If an nNOS molecule binds NO, it is placed in the inactive cycle and
the rate-limiting step becomes the O2-dependent
decay of the NO complex (29). Once decay occurs, the enzyme can bind O2 and rejoin the active cycle.
|
Mutation of Trp-409 to Phe or Tyr appears to effect the rate-limiting step in both cycles of nNOS. In the active cycle, our NADPH oxidation measurements suggest the mutants have a slower electron flow to the heme relative to wild type. Because mutant cytochrome c reduction rates were normal, it is the flavin-to-heme reduction step that is likely slowed. Indeed, the equilibrium reached between ferric and ferrous heme during anaerobic NADPH-dependent reduction is greatly shifted toward ferric in both Trp-409 mutants compared with wild type.3 This is consistent with structural and resonance Raman data that predicts the indole nitrogen of Trp-409 and forms a hydrogen bond with the cysteine thiolate heme ligand in nNOS (see Fig. 1), and loss of this hydrogen bond by mutation to Phe or Tyr should increase the negative charge density on the cysteine thiolate and thus lower the reduction potential of the heme iron (17, 30).
A slower rate of heme reduction would slow NO synthesis by any Trp-409 mutant nNOS molecules present in the active cycle relative to the wild type (27, 28). However, we saw that mutant rates of NO synthesis were actually greater than the wild type. This could occur if the mutations minimized partitioning of enzyme molecules into the inactive cycle (i.e. heme-NO complex) during the steady-state. This appears to be the case, because we observed little or no NO complex accumulation for either Trp-409 mutant in the steady-state. Thus, it appears that the Trp-409 mutations offset their negative effect on heme reduction by allowing a greater proportion of the enzyme to circulate in the active cycle during the steady-state. Why does this occur? There are several possibilities. (a) An increase in cysteine thiolate electronegativity resulting from the loss of the Trp-409 hydrogen bond should weaken the heme-NO bond (31). (b) Slower heme reduction in the mutants might favor formation of the ferric-NO species during the steady-state from which NO more rapidly dissociates (32). (c) Reactivity of the heme-NO complex toward O2 may increase, speeding the return of enzyme molecules to the active cycle. (d) Conversion from a 6- to 5-coordinate ferrous-NO complex may occur (33), although NO generally dissociates slower from 5-coordinate than from 6-coordinate ferrous hemes (34). We are presently working to distinguish between these and other potential mechanisms.
Given the hyperactivity of the Trp-409 mutants, it is astonishing that
a Trp appears at this position in all 29 NOSs sequenced to date. This
implies that in nature the most "appropriate" form of NOS may not
be a more catalytically active form. Why is this so? Although a
definitive answer is still forthcoming, we suspect that this Trp is
conserved either to ensure an appropriate rate of heme reduction or to
maintain NO complex formation and its resultant effect on enzyme
O2 response (29, 35, 36).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Qian Wang for her expert technical assistance.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants GM51491 (to D. J. S.) and HL58883 (to E. D. G. and J. A. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Established Investigator of the American Heart Association. To whom correspondence should be addressed: Immunology NB-3, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-6950; E-mail: stuehrd@ccf.org.
2 N. Sennequier and D. J. Stuehr, unpublished observation.
3 S. Adak and D. J. Stuehr, unpublished observation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
NO, nitric oxide;
NOS, NO synthase;
CaM, calmodulin;
EPPS, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid;
H4B, (6R)-5,6,7,8-tetrahydro-L-biopterin;
NOHA, N
-hydroxy-L-arginine;
nNOS, neuronal NO synthase;
DTT, dithiothreitol.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Craven, S. E., and Bredt, D. S. (1998) Cell 93, 495-498[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | MacMicking, J., Xie, Q.-w., and Nathan, C. (1997) Annu. Rev. Immunol. 15, 323-350[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Michel, T., and Feron, O. (1997) J. Clin. Invest. 100, 2146-2152[Medline] [Order article via Infotrieve] |
| 4. | Stuehr, D. J. (1999) Biochim. Biophys. Acta 1411, 217-230[Medline] [Order article via Infotrieve] |
| 5. | Marletta, M. A., Hurshman, A. R., and Rusche, K. M. (1998) Curr. Opin. Chem. Biol. 2, 656-663[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Hemmens, B., and Mayer, B. (1997) in Methods in Molecular Biology (Titheradge, M. A., ed), Vol. 100 , pp. 1-32, Humana Press, Totowa, NJ |
| 7. | Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Snyder, S. H. (1991) Nature 351, 714-718[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Ruan, J.,
Xie, Q.,
Hutchinson, N.,
Cho, H.,
Wolfe, G. C.,
and Nathan, C.
(1996)
J. Biol. Chem.
271,
22679-22686 |
| 9. |
Abu-Soud, H. M.,
and Stuehr, D. J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10769-10772 |
| 10. |
Abu-Soud, H. M.,
Gachhui, R.,
Raushel, F. M.,
and Stuehr, D. J.
(1997)
J. Biol. Chem.
272,
17349-17353 |
| 11. |
Bec, N.,
Gorren, A. C. F.,
Voelker, C.,
Mayer, B.,
and Lange, R.
(1998)
J. Biol. Chem.
273,
13502-13508 |
| 12. | Fischmann, T. O., Hruza, A., DaNiu, X., Fossetta, J. D., Lunn, C. A., Dolphin, E., Prongay, A. J., Paul, R., Lundell, D. J., Narula, S. K., and Weber, P. C. (1999) Nat. Struct. Biol. 6, 233-242[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Crane, B. R.,
Arvai, A. S.,
Ghosh, D. K.,
Wu, C.,
Getzoff, E. D.,
Stuehr, D. J.,
and Tainer, J. A.
(1998)
Science
279,
2121-2126 |
| 14. | Raman, C. S., Li, H., Martasek, P., Kral, V., Masters, B. S. S., and Poulos, T. M. (1998) Cell 95, 939-950[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Goodin, D. B., Davidson, M. G., Roe, J. A., Mauk, A. G., and Smith, M. (1991) Biochemistry 30, 4953-4962[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Sundaramoorthy, M., Terner, J., and Poulos, T. L. (1995) Structure 3, 1367-1377[Medline] [Order article via Infotrieve] |
| 17. |
Crane, B. R.,
Arvai, A. S.,
Gachhui, R.,
Wu, C.,
Ghosh, D. K.,
Getzoff, E. D.,
Stuehr, D. J.,
and Tainer, J. A.
(1997)
Science
278,
425-431 |
| 18. | Presta, A., Weber-Main, A. M., Stankovich, M. T., and Stuehr, D. J. (1998) J. Am. Chem. Soc. 120, 9460-9465[CrossRef] |
| 19. |
Abu-Soud, H. M.,
Wang, J.,
Rousseau, D. L.,
Fukuto, J.,
Ignarro, L. J.,
and Stuehr, D. J.
(1994)
J. Biol. Chem.
270,
22997-23006 |
| 20. | Tsubaki, M., Hiwatashi, A., Ichikawa, Y., Fujimoto, Y., Ikekawa, N., and Hori, H. (1988) Biochemistry 27, 4856-4862[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Wu, C., Zhang, J., Abu-Soud, H. M., Ghosh, D. K., and Stuehr, D. J. (1996) Biochem. Biophys. Res. Commun. 22, 439-444 |
| 22. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 23. | Rusche, K. M., Spiering, M. M., and Marletta, M. A. (1998) Biochemistry 37, 15503-15512[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | McMillan, K., and Masters, B. S. S. (1993) Biochemistry 32, 9875-9880[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Wang, J.,
Rousseau, D. L.,
Abu-Soud, H. M.,
and Stuehr, D. J.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10512-10516 |
| 26. |
Goodin, D. B.,
and Roe, J. A.
(1993)
J. Biol. Chem.
268,
20037-20045 |
| 27. |
Gachhui, R.,
Abu-Soud, H. M.,
Ghosh, D. K.,
Presta, A.,
Blazing, M. A.,
Mayer, B.,
George, S. E.,
and Stuehr, D. J.
(1998)
J. Biol. Chem.
273,
5451-5454 |
| 28. |
Nishida, C. R.,
and Ortiz de Montellano, P. R.
(1998)
J. Biol. Chem.
273,
5566-5571 |
| 29. |
Abu-Soud, H. M.,
Rousseau, D. L.,
and Stuehr, D. J.
(1996)
J. Biol. Chem.
271,
32515-32518 |
| 30. | Wang, J., Stuehr, D. J., and Rousseau, D. L. (1997) Biochemistry 36, 4595-4606[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Yoshimura, T. (1995) in Bioradicals Detected by ESR Spectroscopy (OhyaNishiguchi, H. , and Packer, L., eds) , pp. 217-235, Birkhauser Verlag, Basel, Switzerland |
| 32. |
Scheele, J. S.,
Bruner, E.,
Kharitonov, V. G.,
Martasek, P.,
Roman, L. J.,
Masters, B. S. S.,
Sharma, V. S.,
and Magde, D.
(1999)
J. Biol. Chem.
274,
13105-13110 |
| 33. | Huang, L., Abu-Soud, H. M., Hille, R., and Stuehr, D. J. (1999) Biochemistry 38, 1912-1920[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Kharitonov, V. G., Sharma, V. S., Magde, D., and Koesling, D. (1997) Biochemistry 36, 6814-6818[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Dweik, R. A., Laskowski, D., Abu-Soud, H. M., Kaneko, F. T., Hutte, R., Stuehr, D. J., and Erzurum, S. C. (1998) J. Clin. Invest. 101, 660-666[Medline] [Order article via Infotrieve] |
| 36. | Prabhakar, N. R., Kumar, G. K., Chang, C.-H., Agani, F. H., and Haxhui, M. A. (1993) Brain Res. 625, 16-22[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
J. Tejero, A. Biswas, Z.-Q. Wang, R. C. Page, M. M. Haque, C. Hemann, J. L. Zweier, S. Misra, and D. J. Stuehr Stabilization and Characterization of a Heme-Oxy Reaction Intermediate in Inducible Nitric-oxide Synthase J. Biol. Chem., November 28, 2008; 283(48): 33498 - 33507. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Haque, K. Panda, J. Tejero, K. S. Aulak, M. A. Fadlalla, A. T. Mustovich, and D. J. Stuehr A connecting hinge represses the activity of endothelial nitric oxide synthase PNAS, May 29, 2007; 104(22): 9254 - 9259. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lane and S. S. Gross Disabling a C-terminal Autoinhibitory Control Element in Endothelial Nitric-oxide Synthase by Phosphorylation Provides a Molecular Explanation for Activation of Vascular NO Synthesis by Diverse Physiological Stimuli J. Biol. Chem., May 17, 2002; 277(21): 19087 - 19094. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Scott, S. Mehta, M. Duggan, A. Bihari, and D. G. McCormack Functional Inhibition of Constitutive Nitric Oxide Synthase in a Rat Model of Sepsis Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1426 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Golser, A. C. F. Gorren, A. Leber, P. Andrew, H.-J. Habisch, E. R. Werner, K. Schmidt, R. C. Venema, and B. Mayer Interaction of Endothelial and Neuronal Nitric-oxide Synthases with the Bradykinin B2 Receptor. BINDING OF AN INHIBITORY PEPTIDE TO THE OXYGENASE DOMAIN BLOCKS UNCOUPLED NADPH OXIDATION J. Biol. Chem., February 25, 2000; 275(8): 5291 - 5296. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Abu-Soud, K. Ichimori, A. Presta, and D. J. Stuehr Electron Transfer, Oxygen Binding, and Nitric Oxide Feedback Inhibition in Endothelial Nitric-oxide Synthase J. Biol. Chem., June 2, 2000; 275(23): 17349 - 17357. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Adak, Q. Wang, and D. J. Stuehr Molecular Basis for Hyperactivity in Tryptophan 409 Mutants of Neuronal NO Synthase J. Biol. Chem., June 2, 2000; 275(23): 17434 - 17439. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Adak, J. Santolini, S. Tikunova, Q. Wang, J. D. Johnson, and D. J. Stuehr Neuronal Nitric-oxide Synthase Mutant (Ser-1412 right-arrow Asp) Demonstrates Surprising Connections between Heme Reduction, NO Complex Formation, and Catalysis J. Biol. Chem., January 5, 2001; 276(2): 1244 - 1252. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Santolini, S. Adak, C. M. L. Curran, and D. J. Stuehr A Kinetic Simulation Model That Describes Catalysis and Regulation in Nitric-oxide Synthase J. Biol. Chem., January 5, 2001; 276(2): 1233 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Wei, Z.-Q. Wang, Q. Wang, A. L. Meade, C. Hemann, R. Hille, and D. J. Stuehr Rapid Kinetic Studies Link Tetrahydrobiopterin Radical Formation to Heme-dioxy Reduction and Arginine Hydroxylation in Inducible Nitric-oxide Synthase J. Biol. Chem., January 5, 2001; 276(1): 315 - 319. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Couture, S. Adak, D. J. Stuehr, and D. L. Rousseau Regulation of the Properties of the Heme-NO Complexes in Nitric-oxide Synthase by Hydrogen Bonding to the Proximal Cysteine J. Biol. Chem., October 5, 2001; 276(41): 38280 - 38288. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Santolini, A. L. Meade, and D. J. Stuehr Differences in Three Kinetic Parameters Underpin the Unique Catalytic Profiles of Nitric-oxide Synthases I, II, and III J. Biol. Chem., December 21, 2001; 276(52): 48887 - 48898. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||